#BEGIN_DRUGCARD DB00635

# AHFS_Codes:
68:04.00

# ATC_Codes:
A07EA03
H02AB07
H02AB15

# Absorption:
Readily absorbed from the gastrointestinal tract. Rayos, the delayed-release formulation, has a 4-hour release time. To compare, the delayed-release formulation has a Tmax of 6.0 - 6.5 hours in healthy male subjects, whereas the immediate-release formulation has a Tmax of 2.0 hours. The rate of absorption, Cmax, and exposure is comparable between formulations.

# Biotransformation:
Prednisone is completely converted to the active metabolite prednisolone by 11β-hydroxysteroid dehydrogenases. It is then further metabolized mainly in the liver. The exposure of prednisolone is 4-6 fold higher than that of prednisone.

# Brand_Mixtures:
Cortab (Biotin + Chlorpheniramine Maleate + D-Pantothenic Acid + Inositol + Nicotinic Acid + Prednisone + Pyridoxine Hydrochloride + Thiamine Mononitrate + Vitamin a + Vitamin B2 + Vitamin D + Vitamin E (Dl-Alpha Tocopheryl Acetate))
Metreton Tab (Chlorpheniramine Maleate + Prednisone + Vitamin C)
Predniderm Tab (Inositol + Pheniramine Maleate + Phosphatidyl Choline + Prednisone + Vitamin a + Vitamin D2 + Vitamin E)
Sterolin Liq (Biotin + Fatty Acids Unsaturated + Inositol + Nicotinic Acid + Pheniramine Maleate + Phosphatidyl Choline + Prednisone + Vitamin a Palmitate + Vitamin B2 + Vitamin D2 + Vitamin E)

# Brand_Names:
Adasone
Ancortone
Apo-prednisone
Betapar
Bicortone
Cartancyl
Colisone
Cortan
Cortancyl
Cortidelt
Cotone
Dacorten
Dacortin
Decortancyl
Decortin
Decortisyl
Dekortin
Delcortin
Dellacort
Dellacort A
Delta Cortelan
Delta E
Delta-cortelan
Delta-cortisone
Delta-cortone
Delta-dome
Deltacortene
Deltacortisone
Deltacortone
Deltasone
Deltison
Deltisona
Deltisone
Deltra
Di-Adreson
Diadreson
Econosone
Encorton
Encortone
Enkorton
Fiasone
Hostacortin
In-Sone
Incocortyl
Juvason
Lisacort
Me-Korti
Metacortandracin
Meticorten
Nisona
Nizon
Novoprednisone
Nurison
Orasone
Origen Prednisone
Panafcort
Panasol
Paracort
Parmenison
Pehacort
Precort
Predeltin
Prednicen-M
Prednicorm
Prednicort
Prednicot
Prednidib
Prednilonga
Prednison
Prednisone Intensol
Prednitone
Prednizon
Prednovister
Presone
Pronison
Rayos
Rectodelt
Retrocortine
Servisone
Sone
Sterapred
Supercortil
Ultracorten
Ultracortene
Winpred
Wojtab
Zenadrid

# CAS_Registry_Number:
53-03-2

# ChEBI_ID:
8382

# Chemical_Formula:
C21H26O5

# Chemical_IUPAC_Name:
(1S,2R,10S,11S,14R,15S)-14-hydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-5,17-dione

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
868426

# Description:
A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver. [PubChem]

# Dosage_Forms:
Concentrate	Oral
Solution	Oral
Tablet	Oral
Tablet, delayed release	Oral

# Drug_Category:
Adrenergic Agents
Anti-inflammatory Agents
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Glucocorticoids

# Drug_Interactions:
Acenocoumarol	The corticosteroid, prednisone, alters the anticoagulant effect, acenocoumarol.
Acetylsalicylic acid	The corticosteroid, prednisone, may decrease the effect of the salicylate, acetylsalicylic acid.
Ambenonium	The corticosteroid, prednisone, may decrease the effect of the anticholinesterase, ambenonium.
Amobarbital	The barbiturate, amobarbital, may decrease the effect of the corticosteroid, prednisone.
Anisindione	The corticosteroid, prednisone, alters the anticoagulant effect of anisindione.
Aprobarbital	The barbiturate, aprobarbital, may decrease the effect of the corticosteroid, prednisone.
Bismuth Subsalicylate	The corticosteroid, prednisone, may decrease the effect of the salicylate, bismuth subsalicylate.
Butabarbital	The barbiturate, butabarbital, may decrease the effect of the corticosteroid, prednisone.
Butalbital	The barbiturate, butalbital, may decrease the effect of the corticosteroid, prednisone.
Butethal	The barbiturate, butethal, may decrease the effect of the corticosteroid, prednisone.
Chlorotrianisene	The estrogenic agent, chlorotrianisene, may increase the effect of corticosteroid, prednisone.
Clomifene	The estrogenic agent, clomifene, may increase the effect of corticosteroid, prednisone.
Conjugated Estrogens	The estrogenic agent may increase the effect of corticosteroid, prednisone.
Dicumarol	The corticosteroid, prednisone, alters the anticoagulant effect of dicumarol.
Diethylstilbestrol	The estrogenic agent, diethylstilbestrol, may increase the effect of corticosteroid, prednisone.
Dihydroquinidine barbiturate	The barbiturate, dihydroquinidine barbiturate, may decrease the effect of the corticosteroid, prednisone.
Edrophonium	The corticosteroid, prednisone, may decrease the effect of the anticholinesterase, edrophonium.
Estradiol	The estrogenic agent, estradiol, may increase the effect of corticosteroid, prednisone.
Estriol	The estrogenic agent, estriol, may increase the effect of corticosteroid, prednisone.
Estrone	The estrogenic agent, estrone, may increase the effect of corticosteroid, prednisone.
Estropipate	The estrogenic agent, estropipate, may increase the effect of corticosteroid, prednisone.
Ethinyl Estradiol	The estrogenic agent, ethinyl estradiol, may increase the effect of corticosteroid, prednisone.
Ethotoin	The enzyme inducer, ethotoin, may decrease the effect of the corticosteroid, prednisone.
F	decreases the effect of cortisone by metabolism alteration.
Fosphenytoin	The enzyme inducer, fosphenytoin, may decrease the effect of the corticosteroid, prednisone.
Glycerol Phenylbutyrate	Use of corticosteroids may cause the breakdown of body protein and increase plasma ammonia levels. Monitor ammonia levels closely when corticosteroids and glycerol pehnylbutyrate are used concomitantly.
Heptabarbital	The barbiturate, heptabarbital, may decrease the effect of the corticosteroid, prednisone.
Hexobarbital	The barbiturate, hexobarbital, may decrease the effect of the corticosteroid, prednisone.
Indacaterol	Concomitant therapy may increase the risk of hypokalemia via intracellular shunting. Monitor for adverse effects and especially for cardiovascular effects associated with hypokalemia.
Itraconazole	The imidazole, itraconazole, may increase the effect and toxicity of the corticosteroid, prednisone.
Ketoconazole	The imidazole, ketoconazole, may increase the effect and toxicity of the corticosteroid, prednisone.
Linagliptin 	CYP3A4 inducers may decrease levels of linagliptin and diminish the hypoglycemic effect of antidiabetic agents. Monitor concomitant therapy closely.
Magnesium salicylate	The corticosteroid, prednisolone, may decrease the effect of magnesium salicylate.
Mephenytoin	The enzyme inducer, mephenytoin, may decrease the effect of the corticosteroid, prednisone.
Mestranol	The estrogenic agent, mestranol, may increase the effect of corticosteroid, prednisone.
Methohexital	The barbiturate, methohexital, may decrease the effect of the corticosteroid, prednisone.
Methylphenobarbital	The barbiturate, methylphenobarbital, may decrease the effect of the corticosteroid, prednisone.
Midodrine	Increased arterial pressure
Neostigmine	The corticosteroid, prednisone, may decrease the effect of the anticholinesterase, neostigmine.
Pentobarbital	The barbiturate, pentobarbital, may decrease the effect of the corticosteroid, prednisone.
Phenobarbital	The barbiturate, phenobarbital, may decrease the effect of the corticosteroid, prednisone.
Phenytoin	The enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, prednisone.
Primidone	The barbiturate, primidone, may decrease the effect of the corticosteroid, prednisone.
Pyridostigmine	The corticosteroid, prednisone, may decrease the effect of the anticholinesterase, pyridostigmine.
Quinestrol	The estrogenic agent, quinestrol, may increase the effect of corticosteroid, prednisone.
Quinidine barbiturate	The barbiturate, quinidine barbiturate, may decrease the effect of the corticosteroid, prednisone.
Rifampin	The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, prednisone.
Salicylate-sodium	The corticosteroid, prednisone, may decrease the effect of the salicylate, salicylate-sodium.
Salsalate	The corticosteroid, prednisone, may decrease the effect of the salicylate, salsalate.
Secobarbital	The barbiturate, secobarbital, may decrease the effect of the corticosteroid, prednisone.
Tacrine	Tacrine and Prednisone may independently exacerbate muscle weakness in myasthenia gravis patients. Monitor for additive muscle weakness effects.
Talbutal	The barbiturate, talbutal, may decrease the effect of the corticosteroid, prednisone.
Trastuzumab	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Trisalicylate-choline	The corticosteroid, prednisone, may decrease the effect of the salicylate, trisalicylate-choline.
Vecuronium	Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Prednisone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy.
Warfarin	The corticosteroid, prednisone, alters the anticoagulant effect of warfarin.

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
1.46

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Very slightly soluble

# Food_Interactions:
Avoid alcohol.
Avoid taking with grapefruit juice.
Take with food to reduce irritation.
When Rayos, the delayed-release tablet, is taken without food, Cmax and bioavailability were lower compared to the fed state.

# GenBank_ID:
Not Available

# Generic_Name:
Prednisone

# HET_ID:
Not Available

# Half_Life:
Half life of both the immediate- and delayed- release formulation is 2 to 3 hours.

# InChI_Identifier:
InChI=1S/C21H26O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-15,18,22,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,18+,19-,20-,21-/m0/s1

# InChI_Key:
InChIKey=XOFYZVNMUHMLCC-ZPOLXVRWSA-N

# Indication:
For the treatment of drug-induced allergic reactions, perennial or seasonal allergic rhinitis, serum sickness, giant cell arteritis acute rheumatic or nonrheumatic carditis, systemic dermatomyositis, systemic lupus erythematosus, atopic dermatitis, contact dermatitis, exfoliative dermatitis, bullous dermatitis herpetiformis, severe seborrheic dermatitis, severe (Stevens-Johnson syndrome) erythema multiforme, mycosis fungoides, pemphigus, severe psoriasis, acute adrenocortical insufficiency, Addison's disease, secondary adrenocortical insufficiency, congenital adrenal hyperplasia, hypercalcemia associated with neoplasms, nonsuppurative thyroiditis, ulceratice colitis, Crohn's disease, acquired hemolytic anemia, congenital hypoplastic anemia, erythroblastopenia, adult secondary thrombocytopenia, adult idiopathic thrombocytopenia purpura, acute or subacute bursitis, epicondylitis, acute nonspecific tenosynovitis, acute or chronic lymphocytic leukemia, Hodgkin's or non-Hodgkin's lynphomas, Waldenstrom's macroglobulinemia, primary brain tumors (adjunct), nephrotic syndrome, tuberculous meningitis, multiple sclerosis, myasthenia gravis. cerebral edema, chorioretinitis, diffuse posterior choroiditis, aleergic conjunctivitis, Herpes zoster ophthalmicus, anterior segment inflammation, iridocyclitis, iritis, keratitis, optoc neuritis, sympathetic ophthalmia, corneal marginal allergic ulcers, symptomatic sarcoidosis, Loeffler's syndrome not manageable by other means, berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy and aspiration pneumonitis.

# KEGG_Compound_ID:
C07370

# KEGG_Drug_ID:
D00473

# LIMS_Drug_ID:
635

# Mechanism_Of_Action:
Prednisone is a glucocorticoid receptor agonist. It is first metabolized in the liver to its active form, prednisolone. Prednisolone crosses cell membranes and binds with high affinity to specific cytoplasmic receptors. The result includes inhibition of leukocyte infiltration at the site of inflammation, interference in the function of mediators of inflammatory response, suppression of humoral immune responses, and reduction in edema or scar tissue. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisone can stimulate secretion of various components of gastric juice. Suppression of the production of corticotropin may lead to suppression of endogenous corticosteroids. Prednisone has slight mineralocorticoid activity, whereby entry of sodium into cells and loss of intracellular potassium is stimulated. This is particularly evident in the kidney, where rapid ion exchange leads to sodium retention and hypertension.

# Melting_Point:
230 - 235 °C (decomposes)

# Molecular_Weight_Avg:
358.4281

# Molecular_Weight_Mono:
358.178023942

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Prednisone Pathway	SMP00440

# PharmGKB_ID:
PA451100

# Pharmacology:
Prednisone, the most commonly-prescribed corticosteroid, is used to treat allograft rejection, asthma, systemic lupus erythematosus, and many other inflammatory states. Prednisone has some mineralocorticoid activity and thus may affect ion exchange in the kidney.

# Predicted_LogP_Hydrophobicity:
2.07

# Predicted_LogS:
-3.5

# Predicted_Water_Solubility:
1.11e-01 g/l

# Primary_Accession_No:
DB00635

# Protein_Binding:
Extensively bound to plasma proteins.

# PubChem_Compound_ID:
5865

# PubChem_Substance_ID:
46508166

# RxList_Link:
http://www.rxlist.com/cgi/generic/pred.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD00340

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Dehydrocortisone
Prednisona [INN-Spanish]
Prednisonum [INN-Latin]

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-06-03 00:23:00 -0600

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Prednisone

# pKa_Isoelectric_Point:
Not Available

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
CYP3A4

# Phase_1_Metabolizing_Enzyme_1_ID:
4512

# Phase_1_Metabolizing_Enzyme_1_Name:
Cytochrome P450 3A4

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Cytochrome P450 3A4
MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMF
DMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISI
AEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYS
MDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICV
FPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSI
IFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVV
NETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFS
KKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLG
GLLQPEKPVVLKVESRDGTVSGA

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P08684

# Phase_1_Metabolizing_Enzyme_2_Gene_Name:
CYP2C19

# Phase_1_Metabolizing_Enzyme_2_ID:
6016

# Phase_1_Metabolizing_Enzyme_2_Name:
Cytochrome P450 2C19

# Phase_1_Metabolizing_Enzyme_2_Protein_Sequence:
>Cytochrome P450 2C19
MDPFVVLVLCLSCLLLLSIWRQSSGRGKLPPGPTPLPVIGNILQIDIKDVSKSLTNLSKI
YGPVFTLYFGLERMVVLHGYEVVKEALIDLGEEFSGRGHFPLAERANRGFGIVFSNGKRW
KEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICS
IIFQKRFDYKDQQFLNLMEKLNENIRIVSTPWIQICNNFPTIIDYFPGTHNKLLKNLAFM
ESDILEKVKEHQESMDINNPRDFIDCFLIKMEKEKQNQQSEFTIENLVITAADLLGAGTE
TTSTTLRYALLLLLKHPEVTAKVQEEIERVVGRNRSPCMQDRGHMPYTDAVVHEVQRYID
LIPTSLPHAVTCDVKFRNYLIPKGTTILTSLTSVLHDNKEFPNPEMFDPRHFLDEGGNFK
KSNYFMPFSAGKRICVGEGLARMELFLFLTFILQNFNLKSLIDPKDLDTTPVVNGFASVP
PFYQLCFIPV

# Phase_1_Metabolizing_Enzyme_2_SwissProt_ID:
P33261

# Drug_Target_1_Cellular_Location:
Cytoplasm. Nucleus. Cytoplasmic in the absence of ligand
nuclear after ligand-binding

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
16597193	Friel PN, Alexander T, Wright JV: Suppression of adrenal function by low-dose prednisone: assessment with 24-hour urinary steroid hormone profiles--a review of five cases. Altern Med Rev. 2006 Mar;11(1):40-6.
16707595	Yano A, Fujii Y, Iwai A, Kageyama Y, Kihara K: Glucocorticoids suppress tumor angiogenesis and in vivo growth of prostate cancer cells. Clin Cancer Res. 2006 May 15;12(10):3003-9.
17062674	Yano A, Fujii Y, Iwai A, Kawakami S, Kageyama Y, Kihara K: Glucocorticoids suppress tumor lymphangiogenesis of prostate cancer cells. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6012-7.
17121036	Liu BG, Li ZY, Du M: [Effects of jingui shenqi pill combined prednisone on expression of glucocorticoid receptor and its clinical effect in treating bullous pemphigoid patients] Zhongguo Zhong Xi Yi Jie He Za Zhi. 2006 Oct;26(10):881-4.
17504182	Diez JJ, Iglesias P: Pharmacological therapy of Cushing's syndrome: drugs and indications. Mini Rev Med Chem. 2007 May;7(5):467-80.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
NR3C1

# Drug_Target_1_GenBank_ID_Gene:
X03225

# Drug_Target_1_GenBank_ID_Protein:
31680

# Drug_Target_1_GeneCard_ID:
NR3C1

# Drug_Target_1_Gene_Name:
NR3C1

# Drug_Target_1_Gene_Sequence:
>2334 bp
ATGGACTCCAAAGAATCATTAACTCCTGGTAGAGAAGAAAACCCCAGCAGTGTGCTTGCT
CAGGAGAGGGGAGATGTGATGGACTTCTATAAAACCCTAAGAGGAGGAGCTACTGTGAAG
GTTTCTGCGTCTTCACCCTCACTGGCTGTCGCTTCTCAATCAGACTCCAAGCAGCGAAGA
CTTTTGGTTGATTTTCCAAAAGGCTCAGTAAGCAATGCGCAGCAGCCAGATCTGTCCAAA
GCAGTTTCACTCTCAATGGGACTGTATATGGGAGAGACAGAAACAAAAGTGATGGGAAAT
GACCTGGGATTCCCACAGCAGGGCCAAATCAGCCTTTCCTCGGGGGAAACAGACTTAAAG
CTTTTGGAAGAAAGCATTGCAAACCTCAATAGGTCGACCAGTGTTCCAGAGAACCCCAAG
AGTTCAGCATCCACTGCTGTGTCTGCTGCCCCCACAGAGAAGGAGTTTCCAAAAACTCAC
TCTGATGTATCTTCAGAACAGCAACATTTGAAGGGCCAGACTGGCACCAACGGTGGCAAT
GTGAAATTGTATACCACAGACCAAAGCACCTTTGACATTTTGCAGGATTTGGAGTTTTCT
TCTGGGTCCCCAGGTAAAGAGACGAATGAGAGTCCTTGGAGATCAGACCTGTTGATAGAT
GAAAACTGTTTGCTTTCTCCTCTGGCGGGAGAAGACGATTCATTCCTTTTGGAAGGAAAC
TCGAATGAGGACTGCAAGCCTCTCATTTTACCGGACACTAAACCCAAAATTAAGGATAAT
GGAGATCTGGTTTTGTCAAGCCCCAGTAATGTAACACTGCCCCAAGTGAAAACAGAAAAA
GAAGATTTCATCGAACTCTGCACCCCTGGGGTAATTAAGCAAGAGAAACTGGGCACAGTT
TACTGTCAGGCAAGCTTTCCTGGAGCAAATATAATTGGTAATAAAATGTCTGCCATTTCT
GTTCATGGTGTGAGTACCTCTGGAGGACAGATGTACCACTATGACATGAATACAGCATCC
CTTTCTCAACAGCAGGATCAGAAGCCTATTTTTAATGTCATTCCACCAATTCCCGTTGGT
TCCGAAAATTGGAATAGGTGCCAAGGATCTGGAGATGACAACTTGACTTCTCTGGGGACT
CTGAACTTCCCTGGTCGAACAGTTTTTTCTAATGGCTATTCAAGCCCCAGCATGAGACCA
GATGTAAGCTCTCCTCCATCCAGCTCCTCAACAGCAACAACAGGACCACCTCCCAAACTC
TGCCTGGTGTGCTCTGATGAAGCTTCAGGATGTCATTATGGAGTCTTAACTTGTGGAAGC
TGTAAAGTTTTCTTCAAAAGAGCAGTGGAAGGACAGCACAATTACCTATGTGCTGGAAGG
AATGATTGCATCATCGATAAAATTCGAAGAAAAAACTGCCCAGCATGCCGCTATCGAAAA
TGTCTTCAGGCTGGAATGAACCTGGAAGCTCGAAAAACAAAGAAAAAAATAAAAGGAATT
CAGCAGGCCACTACAGGAGTCTCACAAGAAACCTCTGAAAATCCTGGTAACAAAACAATA
GTTCCTGCAACGTTACCACAACTCACCCCTACCCTGGTGTCACTGTTGGAGGTTATTGAA
CCTGAAGTGTTATATGCAGGATATGATAGCTCTGTTCCAGACTCAACTTGGAGGATCATG
ACTACGCTCAACATGTTAGGAGGGCGGCAAGTGATTGCAGCAGTGAAATGGGCAAAGGCA
ATACCAGGTTTCAGGAACTTACACCTGGATGACCAAATGACCCTACTGCAGTACTCCTGG
ATGTTTCTTATGGCATTTGCTCTGGGGTGGAGATCATATAGACAATCAAGTGCAAACCTG
CTGTGTTTTGCTCCTGATCTGATTATTAATGAGCAGAGAATGACTCTACCCTGCATGTAC
GACCAATGTAAACACATGCTGTATGTTTCCTCTGAGTTACACAGGCTTCAGGTATCTTAT
GAAGAGTATCTCTGTATGAAAACCTTACTGCTTCTCTCTTCAGTTCCTAAGGACGGTCTG
AAGAGCCAAGAGCTATTTGATGAAATTAGAATGACCTACATCAAAGAGCTAGGAAAAGCC
ATTGTCAAGAGGGAAGGAAACTCCAGCCAGAACTGGCAGCGGTTTTATCAACTGACAAAA
CTCTTGGATTCTATGCATGAAGTGGTTGAAAATCTCCTTAACTATTGCTTCCAAACATTT
TTGGATAAGACCATGAGTATTGAATTCCCCGAGATGTTAGCTGAAATCATCACCAATCAG
ATACCAAAATATTCAAATGGAAATATCAAAAAACTTCTGTTTCATCAAAAGTGA

# Drug_Target_1_General_Function:
Involved in DNA binding

# Drug_Target_1_General_References:
10391209	Cargill M, Altshuler D, Ireland J, Sklar P, Ardlie K, Patil N, Shaw N, Lane CR, Lim EP, Kalyanaraman N, Nemesh J, Ziaugra L, Friedland L, Rolfe A, Warrington J, Lipshutz R, Daley GQ, Lander ES: Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet. 1999 Jul;22(3):231-8.
10477749	Schneikert J, Hubner S, Martin E, Cato AC: A nuclear action of the eukaryotic cochaperone RAP46 in downregulation of glucocorticoid receptor activity. J Cell Biol. 1999 Sep 6;146(5):929-40.
10566686	Rivers C, Levy A, Hancock J, Lightman S, Norman M: Insertion of an amino acid in the DNA-binding domain of the glucocorticoid receptor as a result of alternative splicing. J Clin Endocrinol Metab. 1999 Nov;84(11):4283-6.
10639135	Diamond MI, Robinson MR, Yamamoto KR: Regulation of expanded polyglutamine protein aggregation and nuclear localization by the glucocorticoid receptor. Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):657-61.
10866662	Mahajan MA, Samuels HH: A new family of nuclear receptor coregulators that integrate nuclear receptor signaling through CREB-binding protein. Mol Cell Biol. 2000 Jul;20(14):5048-63.
10898924	Feng J, Zheng J, Bennett WP, Heston LL, Jones IR, Craddock N, Sommer SS: Five missense variants in the amino-terminal domain of the glucocorticoid receptor: no association with puerperal psychosis or schizophrenia. Am J Med Genet. 2000 Jun 12;96(3):412-7.
10902803	Kayes-Wandover KM, White PC: Steroidogenic enzyme gene expression in the human heart. J Clin Endocrinol Metab. 2000 Jul;85(7):2519-25.
11238589	Strickland I, Kisich K, Hauk PJ, Vottero A, Chrousos GP, Klemm DJ, Leung DY: High constitutive glucocorticoid receptor beta in human neutrophils enables them to reduce their spontaneous rate of cell death in response to corticosteroids. J Exp Med. 2001 Mar 5;193(5):585-93.
11344238	Dobson MG, Redfern CP, Unwin N, Weaver JU: The N363S polymorphism of the glucocorticoid receptor: potential contribution to central obesity in men and lack of association with other risk factors for coronary heart disease and diabetes mellitus. J Clin Endocrinol Metab. 2001 May;86(5):2270-4.
11435610	Yudt MR, Cidlowski JA: Molecular identification and characterization of a and b forms of the glucocorticoid receptor. Mol Endocrinol. 2001 Jul;15(7):1093-103.
11555652	Wallace AD, Cidlowski JA: Proteasome-mediated glucocorticoid receptor degradation restricts transcriptional signaling by glucocorticoids. J Biol Chem. 2001 Nov 16;276(46):42714-21. Epub 2001 Sep 12.
11589680	Ruiz M, Lind U, Gafvels M, Eggertsen G, Carlstedt-Duke J, Nilsson L, Holtmann M, Stierna P, Wikstrom AC, Werner S: Characterization of two novel mutations in the glucocorticoid receptor gene in patients with primary cortisol resistance. Clin Endocrinol (Oxf). 2001 Sep;55(3):363-71.
11701741	Kino T, Stauber RH, Resau JH, Pavlakis GN, Chrousos GP: Pathologic human GR mutant has a transdominant negative effect on the wild-type GR by inhibiting its translocation into the nucleus: importance of the ligand-binding domain for intracellular GR trafficking. J Clin Endocrinol Metab. 2001 Nov;86(11):5600-8.
11932321	Mendonca BB, Leite MV, de Castro M, Kino T, Elias LL, Bachega TA, Arnhold IJ, Chrousos GP, Latronico AC: Female pseudohermaphroditism caused by a novel homozygous missense mutation of the GR gene. J Clin Endocrinol Metab. 2002 Apr;87(4):1805-9.
12000743	Wang Z, Frederick J, Garabedian MJ: Deciphering the phosphorylation "code" of the glucocorticoid receptor in vivo. J Biol Chem. 2002 Jul 19;277(29):26573-80. Epub 2002 May 8.
12050230	Vottero A, Kino T, Combe H, Lecomte P, Chrousos GP: A novel, C-terminal dominant negative mutation of the GR causes familial glucocorticoid resistance through abnormal interactions with p160 steroid receptor coactivators. J Clin Endocrinol Metab. 2002 Jun;87(6):2658-67.
12144530	Tian S, Poukka H, Palvimo JJ, Janne OA: Small ubiquitin-related modifier-1 (SUMO-1) modification of the glucocorticoid receptor. Biochem J. 2002 Nov 1;367(Pt 3):907-11.
12151000	Bledsoe RK, Montana VG, Stanley TB, Delves CJ, Apolito CJ, McKee DD, Consler TG, Parks DJ, Stewart EL, Willson TM, Lambert MH, Moore JT, Pearce KH, Xu HE: Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition. Cell. 2002 Jul 12;110(1):93-105.
12415108	Wong CW, McNally C, Nickbarg E, Komm BS, Cheskis BJ: Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade. Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):14783-8. Epub 2002 Nov 1.
12686538	Kauppi B, Jakob C, Farnegardh M, Yang J, Ahola H, Alarcon M, Calles K, Engstrom O, Harlan J, Muchmore S, Ramqvist AK, Thorell S, Ohman L, Greer J, Gustafsson JA, Carlstedt-Duke J, Carlquist M: The three-dimensional structures of antagonistic and agonistic forms of the glucocorticoid receptor ligand-binding domain: RU-486 induces a transconformation that leads to active antagonism. J Biol Chem. 2003 Jun 20;278(25):22748-54. Epub 2003 Apr 9.
1704018	Hurley DM, Accili D, Stratakis CA, Karl M, Vamvakopoulos N, Rorer E, Constantine K, Taylor SI, Chrousos GP: Point mutation causing a single amino acid substitution in the hormone binding domain of the glucocorticoid receptor in familial glucocorticoid resistance. J Clin Invest. 1991 Feb;87(2):680-6.
1707881	Encio IJ, Detera-Wadleigh SD: The genomic structure of the human glucocorticoid receptor. J Biol Chem. 1991 Apr 15;266(11):7182-8.
1958537	Govindan MV, Pothier F, Leclerc S, Palaniswami R, Xie B: Human glucocorticoid receptor gene promotor-homologous down regulation. J Steroid Biochem Mol Biol. 1991;40(1-3):317-23.
2026589	Leclerc S, Xie BX, Roy R, Govindan MV: Purification of a human glucocorticoid receptor gene promoter-binding protein. Production of polyclonal antibodies against the purified factor. J Biol Chem. 1991 May 15;266(14):8711-9.
2867473	Hollenberg SM, Weinberger C, Ong ES, Cerelli G, Oro A, Lebo R, Thompson EB, Rosenfeld MG, Evans RM: Primary structure and expression of a functional human glucocorticoid receptor cDNA. Nature. 1985 Dec 19-1986 Jan 1;318(6047):635-41.
3841189	Weinberger C, Hollenberg SM, Rosenfeld MG, Evans RM: Domain structure of human glucocorticoid receptor and its relationship to the v-erb-A oncogene product. Nature. 1985 Dec 19-1986 Jan 1;318(6047):670-2.
7683692	Malchoff DM, Brufsky A, Reardon G, McDermott P, Javier EC, Bergh CH, Rowe D, Malchoff CD: A mutation of the glucocorticoid receptor in primary cortisol resistance. J Clin Invest. 1993 May;91(5):1918-25.
8316249	Ashraf J, Thompson EB: Identification of the activation-labile gene: a single point mutation in the human glucocorticoid receptor presents as two distinct receptor phenotypes. Mol Endocrinol. 1993 May;7(5):631-42.
8358712	Moalli PA, Pillay S, Krett NL, Rosen ST: Alternatively spliced glucocorticoid receptor messenger RNAs in glucocorticoid-resistant human multiple myeloma cells. Cancer Res. 1993 Sep 1;53(17):3877-9.
8358735	Powers JH, Hillmann AG, Tang DC, Harmon JM: Cloning and expression of mutant glucocorticoid receptors from glucocorticoid-sensitive and -resistant human leukemic cells. Cancer Res. 1993 Sep 1;53(17):4059-65.
8445027	Karl M, Lamberts SW, Detera-Wadleigh SD, Encio IJ, Stratakis CA, Hurley DM, Accili D, Chrousos GP: Familial glucocorticoid resistance caused by a splice site deletion in the human glucocorticoid receptor gene. J Clin Endocrinol Metab. 1993 Mar;76(3):683-9.
9150737	Koper JW, Stolk RP, de Lange P, Huizenga NA, Molijn GJ, Pols HA, Grobbee DE, Karl M, de Jong FH, Brinkmann AO, Lamberts SW: Lack of association between five polymorphisms in the human glucocorticoid receptor gene and glucocorticoid resistance. Hum Genet. 1997 May;99(5):663-8.
9154805	Henriksson A, Almlof T, Ford J, McEwan IJ, Gustafsson JA, Wright AP: Role of the Ada adaptor complex in gene activation by the glucocorticoid receptor. Mol Cell Biol. 1997 Jun;17(6):3065-73.
9590696	Fryer CJ, Archer TK: Chromatin remodelling by the glucocorticoid receptor requires the BRG1 complex. Nature. 1998 May 7;393(6680):88-91.

# Drug_Target_1_HGNC_ID:
HGNC:7978

# Drug_Target_1_HPRD_ID:
00679

# Drug_Target_1_ID:
871

# Drug_Target_1_Locus:
5q31.3

# Drug_Target_1_Molecular_Weight:
85660

# Drug_Target_1_Name:
Glucocorticoid receptor

# Drug_Target_1_Number_of_Residues:
777

# Drug_Target_1_PDB_ID:
1NHZ

# Drug_Target_1_Pathway:
Prednisolone Pathway	SMP00441
Prednisone Pathway	SMP00440

# Drug_Target_1_Pfam_Domain_Function:
PF00104	Hormone_recep
PF00105	zf-C4
PF02155	GCR

# Drug_Target_1_Protein_Sequence:
>Glucocorticoid receptor
MDSKESLTPGREENPSSVLAQERGDVMDFYKTLRGGATVKVSASSPSLAVASQSDSKQRR
LLVDFPKGSVSNAQQPDLSKAVSLSMGLYMGETETKVMGNDLGFPQQGQISLSSGETDLK
LLEESIANLNRSTSVPENPKSSASTAVSAAPTEKEFPKTHSDVSSEQQHLKGQTGTNGGN
VKLYTTDQSTFDILQDLEFSSGSPGKETNESPWRSDLLIDENCLLSPLAGEDDSFLLEGN
SNEDCKPLILPDTKPKIKDNGDLVLSSPSNVTLPQVKTEKEDFIELCTPGVIKQEKLGTV
YCQASFPGANIIGNKMSAISVHGVSTSGGQMYHYDMNTASLSQQQDQKPIFNVIPPIPVG
SENWNRCQGSGDDNLTSLGTLNFPGRTVFSNGYSSPSMRPDVSSPPSSSSTATTGPPPKL
CLVCSDEASGCHYGVLTCGSCKVFFKRAVEGQHNYLCAGRNDCIIDKIRRKNCPACRYRK
CLQAGMNLEARKTKKKIKGIQQATTGVSQETSENPGNKTIVPATLPQLTPTLVSLLEVIE
PEVLYAGYDSSVPDSTWRIMTTLNMLGGRQVIAAVKWAKAIPGFRNLHLDDQMTLLQYSW
MFLMAFALGWRSYRQSSANLLCFAPDLIINEQRMTLPCMYDQCKHMLYVSSELHRLQVSY
EEYLCMKTLLLLSSVPKDGLKSQELFDEIRMTYIKELGKAIVKREGNSSQNWQRFYQLTK
LLDSMHEVVENLLNYCFQTFLDKTMSIEFPEMLAEIITNQIPKYSNGNIKKLLFHQK

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Receptor for glucocorticoids (GC). Has a dual mode of action:as a transcription factor that binds to glucocorticoid response elements (GRE) and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Could act as a coactivator for STAT5-dependent transcription upon growth hormone (GH) stimulation and could reveal an essential role of hepatic GR in the control of body growth

# Drug_Target_1_SwissProt_ID:
P04150

# Drug_Target_1_SwissProt_Name:
GCR_HUMAN

# Drug_Target_1_Synonyms:
GR

# Drug_Target_1_Theoretical_pI:
6.31

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Endoplasmic reticulum
endoplasmic reticulum membrane
single-pass type II membrane protein

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
20634231	Raza K, Hardy R, Cooper MS: The 11beta-hydroxysteroid dehydrogenase enzymes--arbiters of the effects of glucocorticoids in synovium and bone. Rheumatology (Oxford). 2010 Nov;49(11):2016-23. doi: 10.1093/rheumatology/keq212. Epub 2010 Jul 15.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
HSD11B1

# Drug_Target_2_GenBank_ID_Gene:
M76665

# Drug_Target_2_GenBank_ID_Protein:
179475

# Drug_Target_2_GeneCard_ID:
HSD11B1

# Drug_Target_2_Gene_Name:
HSD11B1

# Drug_Target_2_Gene_Sequence:
>879 bp
ATGGCTTTTATGAAAAAATATCTCCTCCCCATTCTGGGGCTCTTCATGGCCTACTACTAC
TATTCTGCAAACGAGGAATTCAGACCAGAGATGCTCCAAGGAAAGAAAGTGATTGTCACA
GGGGCCAGCAAAGGGATCGGAAGAGAGATGGCTTATCATCTGGCGAAGATGGGAGCCCAT
GTGGTGGTGACAGCGAGGTCAAAAGAAACTCTACAGAAGGTGGTATCCCACTGCCTGGAG
CTTGGAGCAGCCTCAGCACACTACATTGCTGGCACCATGGAAGACATGACCTTCGCAGAG
CAATTTGTTGCCCAAGCAGGAAAGCTCATGGGAGGACTAGACATGCTCATTCTCAACCAC
ATCACCAACACTTCTTTGAATCTTTTTCATGATGATATTCACCATGTGCGCAAAAGCATG
GAAGTCAACTTCCTCAGTTACGTGGTCCTGACTGTAGCTGCCTTGCCCATGCTGAAGCAG
AGCAATGGAAGCATTGTTGTCGTCTCCTCTCTGGCTGGGAAAGTGGCTTATCCAATGGTT
GCTGCCTATTCTGCAAGCAAGTTTGCTTTGGATGGGTTCTTCTCCTCCATCAGAAAGGAA
TATTCAGTGTCCAGGGTCAATGTATCAATCACTCTCTGTGTTCTTGGCCTCATAGACACA
GAAACAGCCATGAAGGCAGTTTCTGGGATAGTCCATATGCAAGCAGCTCCAAAGGAGGAA
TGTGCCCTGGAGATCATCAAAGGGGGAGCTCTGCGCCAAGAAGAAGTGTATTATGACAGC
TCACTCTGGACCACTCTTCTGATCAGAAATCCATGCAGGAAGATCCTGGAATTTCTCTAC
TCAACGAGCTATAATATGGACAGATTCATAAACAAGTAG

# Drug_Target_2_General_Function:
Lipid transport and metabolism

# Drug_Target_2_General_References:
1885595	Tannin GM, Agarwal AK, Monder C, New MI, White PC: The human gene for 11 beta-hydroxysteroid dehydrogenase. Structure, tissue distribution, and chromosomal localization. J Biol Chem. 1991 Sep 5;266(25):16653-8.

# Drug_Target_2_HGNC_ID:
HGNC:5208

# Drug_Target_2_HPRD_ID:
07042

# Drug_Target_2_ID:
364

# Drug_Target_2_Locus:
1q32-q41

# Drug_Target_2_Molecular_Weight:
32270

# Drug_Target_2_Name:
Corticosteroid 11-beta-dehydrogenase isozyme 1

# Drug_Target_2_Number_of_Residues:
291

# Drug_Target_2_PDB_ID:
1XU9

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00106	adh_short

# Drug_Target_2_Protein_Sequence:
>Corticosteroid 11-beta-dehydrogenase isozyme 1
AFMKKYLLPILGLFMAYYYYSANEEFRPEMLQGKKVIVTGASKGIGREMAYHLAKMGAHV
VVTARSKETLQKVVSHCLELGAASAHYIAGTMEDMTFAEQFVAQAGKLMGGLDMLILNHI
TNTSLNLFHDDIHHVRKSMEVNFLSYVVLTVAALPMLKQSNGSIVVVSSLAGKVAYPMVA
AYSASKFALDGFFSSIRKEYSVSRVNVSITLCVLGLIDTETAMKAVSGIVHMQAAPKEEC
ALEIIKGGALRQEEVYYDSSLWTTLLIRNPCRKILEFLYSTSYNMDRFINK

# Drug_Target_2_Reaction:
an 11beta-hydroxysteroid + NADP+ = an 11-oxosteroid + NADPH + H+

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Catalyzes reversibly the conversion of cortisol to the inactive metabolite cortisone. Catalyzes reversibly the conversion of 7-ketocholesterol to 7-beta-hydroxycholesterol. In intact cells, the reaction runs only in one direction, from 7- ketocholesterol to 7-beta-hydroxycholesterol

# Drug_Target_2_SwissProt_ID:
P28845

# Drug_Target_2_SwissProt_Name:
DHI1_HUMAN

# Drug_Target_2_Synonyms:
11-DH
11-beta-HSD1
11-beta-hydroxysteroid dehydrogenase 1
EC 1.1.1.146

# Drug_Target_2_Theoretical_pI:
8.77

# Drug_Target_2_Transmembrane_Regions:
7-23

#END_DRUGCARD DB00635
